Daily online MRI for improving radiotherapy precision
Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy (MRIgRT)
This study is testing a new way to use MRI scans during radiotherapy to help doctors target tumors more accurately and protect healthy tissue in patients with adenocarcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 173 (estimated) |
| Ages | 3 Years and up |
| Sex | All |
| Sponsor | Institute of Cancer Research, United Kingdom Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Sutton, Surrey) |
| Trial ID | NCT02973828 on ClinicalTrials.gov |
What this trial studies
This study focuses on developing a new imaging approach using magnetic resonance imaging (MRI) to enhance the accuracy of radiotherapy for patients with adenocarcinoma. By integrating MRI with a radiotherapy machine, the study aims to create high-quality images that can better differentiate between tumor and normal tissue, reducing unnecessary radiation exposure. The research will involve both patient and non-patient volunteers to optimize imaging techniques and establish workflows for clinical application. The ultimate goal is to improve treatment adaptation and quality assurance in radiotherapy.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed invasive carcinoma of specific target sites who are planned to receive radiotherapy.
Not a fit: Patients with conditions that contraindicate MRI or those who do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce radiation exposure to healthy tissues while improving tumor targeting during radiotherapy.
How similar studies have performed: While the integration of MRI in radiotherapy is a growing field, this specific approach using MR Linac technology is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All volunteers must undergo and satisfy MRI safety screening * Non-patient volunteers must have no known (or suspected) significant medical condition and be 18 years of age * Patient volunteers must have histologically confirmed invasive carcinoma of the tumour/target sites listed in this protocol and be under the care of a Clinical Oncologist at the Royal Marsden NHS Foundation Trust or The Christie NHS Foundation Trust and patients be planned to receive radiotherapy to target site to be imaged * All volunteers must be willing and able to provide informed consent/assent for the study * Paediatric patient volunteers between the ages of 3 and 18 years, will have consent provided by his or her legal guardian who is 18 years of age * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Exclusion Criteria: Any conditions that would be a contra-indication to MRI including: * Failure to satisfy the MRI safety screening * Implanted pacemakers and/or pacing wires * Cochlear implants * Programmable hydrocephalus shunts * Implanted neurostimulation systems * Implanted drug infusion pumps * Ferromagnetic implants And additional conditions that may place volunteers at increased risk from MRI procedures including: * Known susceptibility to seizures or migraines * Fever, reduced thermal regulatory capabilities or increased sensitivity to raised body temperature (for example pregnant women)
Where this trial is running
Sutton, Surrey
- The Royal Marsden NHS Foundation Trust — Sutton, Surrey, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Robert Huddart — Institute of Cancer Research, United Kingdom
- Study coordinator: Greta Bucinskaite
- Email: greta.bucinskaite@rmh.nhs.uk
- Phone: +44 20 3186 5157
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.